Literature DB >> 12679317

Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma.

Michael Duff1, Philip P Stapleton, Juan R Mestre, Sirish Maddali, Gordon P Smyth, Zhaoping Yan, Tracy A Freeman, John M Daly.   

Abstract

BACKGROUND: Melanoma inhibits macrophage tumoricidal activity and increases the expression of cyclooxygenase-2 (COX-2). In this study, we sought to determine whether inhibition of COX-2 could restore macrophage function and hence maximize the antitumor activity of the immune stimulant interferon gamma (IFN gamma).
METHODS: Peritoneal macrophages were exposed to B16 melanoma-conditioned medium for 24 hours with or without the COX-2 inhibitor NS-398 and then were stimulated with lipopolysaccharide and IFN gamma. Cytotoxic activity, nitrite production, and cytokine production by the stimulated macrophages were measured. In addition, B16 melanoma cells were implanted intradermally into mice treated with IFN gamma (14,000 U on alternate days) alone or with a combination of IFN gamma and a COX-2 inhibitor (NS-398 or nimesulide). Mice were assessed for tumor growth and survival.
RESULTS: Macrophage cytotoxicity and nitrite production were significantly suppressed by melanoma-conditioned medium (P <.01). This was prevented by 200 micro M of NS-398 (P <.05). In vivo, combined treatment with IFN gamma and a COX-2 inhibitor caused a significant inhibition of tumor growth (P <.01) and improved survival (P =.02) compared with controls.
CONCLUSIONS: COX-2 inhibition reversed melanoma-induced suppression of macrophage function, and combined treatment of IFN gamma plus a COX-2 inhibitor was maximally effective in reducing tumor growth and improving survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679317     DOI: 10.1245/aso.2003.04.033

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  The inhibition of lung colonization of B16-F10 melanoma cells in EFA-deficient animals is related to enhanced apoptosis and reduced angiogenesis.

Authors:  Antonella Mannini; Anna Calzolari; Lido Calorini; Gabriele Mugnai; Salvatore Ruggieri
Journal:  Clin Exp Metastasis       Date:  2006-09-22       Impact factor: 5.150

2.  Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.

Authors:  Clara Curiel-Lewandrowski; Susan M Swetter; Janine G Einspahr; Chiu-Hsieh Hsu; Ray Nagle; Paul Sagerman; Joseph Tangrea; Howard Parnes; David S Alberts; Hsiao-Hui Chow
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

Review 3.  Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity.

Authors:  Mahmoud R Hussein
Journal:  Int J Exp Pathol       Date:  2006-06       Impact factor: 1.925

4.  Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion.

Authors:  Neelam Sharma-Walia; Arun George Paul; Virginie Bottero; Sathish Sadagopan; Mohanan Valiya Veettil; Nagaraj Kerur; Bala Chandran
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

Review 5.  Chemoprevention of melanoma.

Authors:  Marie-France Demierre; Glenn Merlino
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

6.  The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production.

Authors:  Jean-Claude Marshall; Amanda L Caissie; Stephanie R Cruess; Jonathan Cools-Lartigue; Miguel N Burnier
Journal:  J Carcinog       Date:  2007-11-27

Review 7.  Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.

Authors:  Laurence Pellerin; Lorry Carrié; Carine Dufau; Laurence Nieto; Bruno Ségui; Thierry Levade; Joëlle Riond; Nathalie Andrieu-Abadie
Journal:  Cancers (Basel)       Date:  2020-10-27       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.